Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Isofol Medical AB (publ)    ISOFOL   SE0009581051

ISOFOL MEDICAL AB (PUBL)

(ISOFOL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq Omx Stockholm
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
16.5 16.5 17.3 16.75 16.2 Last
229053 188083 77818 111675 110234 Volume
-5.17% 0.00% +4.85% -3.18% -3.28% Change
Financials
Sales 2020 50,3 M 5,90 M 5,90 M
Net income 2020 -165 M -19,4 M -19,4 M
Net cash position 2020 74,4 M 8,72 M 8,72 M
P/E ratio 2020 -5,87x
Yield 2020 -
Sales 2021 14,5 M 1,70 M 1,70 M
Net income 2021 -149 M -17,5 M -17,5 M
Net cash position 2021 24,2 M 2,84 M 2,84 M
P/E ratio 2021 -6,91x
Yield 2021 -
Capitalization 1 351 M 159 M 158 M
EV / Sales 2020 25,4x
EV / Sales 2021 91,7x
Nbr of Employees 12
Free-Float 100%
More Financials
Company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Isofol Medical AB (publ)
Trading Rating : Investor Rating : -
More Ratings
All news about ISOFOL MEDICAL AB (PUBL)
11/15DNB MARKETS - ISOFOL MEDICAL : Full steam ahead
AQ
11/02DNB MARKETS : Isofol Medical - Licensing deal for Canada
AQ
11/02ISOFOL MEDICAL : Invitation to a conference call and webcast by Isofol in connec..
AQ
11/02ISOFOL MEDICAL : announces licensing agreement for Paladin Labs Inc. to commerci..
AQ
10/19ISOFOL MEDICAL : Positive Momentum Ahead of AGENT Verdict
AQ
09/30ISOFOL MEDICAL : 55 % Overall Response Rate on the safety extension cohorts of t..
AQ
09/01ISOFOL MEDICAL : Strengthened patent protection for arfolitixorin in Japan
AQ
More news
News in other languages on ISOFOL MEDICAL AB (PUBL)

- No features available -

More news
Chart ISOFOL MEDICAL AB (PUBL)
Duration : Period :
Isofol Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ISOFOL MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 28,00 SEK
Last Close Price 16,20 SEK
Spread / Highest target 116%
Spread / Average Target 72,8%
Spread / Lowest Target 29,6%
EPS Revisions
Managers
NameTitle
Jarl Ulf Birger Jungnelius Chief Executive Officer & Director
Pär-Ola Mannefred Chairman
Gustaf Albért Chief Financial Officer
Karin Ganlöv Senior Medical Director
Roger Tell Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ISOFOL MEDICAL AB (PUBL)-19.80%159
MERCK KGAA27.86%70 594
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD90.24%20 216
KYOWA KIRIN CO., LTD.10.18%14 870
BETTA PHARMACEUTICALS CO., LTD.38.95%5 660
YUHAN CORPORATION36.15%3 462